or Try an Advanced Search...

    Technical Analysis for SABS - SAB Biotherapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.64 0.00% 0.00
    SABS closed unchanged on Friday, May 31, 2024, on 27 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical SABS trend table...
    Date Alert Name Type % Chg
    Hammer Candlestick Bullish 0.00%
    Doji - Bullish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Calm After Storm Range Contraction -6.38%
    NR7 Range Contraction -6.38%
    Narrow Range Bar Range Contraction -6.38%
    Older End-of-Day Signals for SABS ...

       Recent Intraday Alerts

    Alert Time
    Down 5% 1 day ago
    Down 3% 1 day ago
    Bearish 180 Entry 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Down 2 % 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SABS Chart by TradingView
    Basic chart:

    Profile

    SAB Biotherapeutics, Inc. Description

    SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Pharmaceutical Immunology Immune System Immunotherapy Diabetes Infectious Diseases Autoimmune Disease Antibodies Antibody Immunotherapies Influenza Genetic Engineering Us Government Human Diseases Transplantation Glycoproteins Polyclonal Antibodies Type 1 Diabetes

    Is SABS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 30 SAB Biotherapeutics announces departure of CFO
    May 30 SAB Biotherapeutics Announces Departure of Chief Financial Officer
    May 21 SAB Biotherapeutics GAAP EPS of -$0.43 beats by $0.60
    May 21 FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
    May 20 SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
    May 6 SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
    Apr 16 SAB Biotherapeutics Provides SAB-142 Trial Update
    Apr 8 SAB Biotherapeutics to Present at INNODIA Annual Meeting
    Apr 4 SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
    Apr 1 SAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
    See more SABS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 10.5
    52 Week Low 2.36
    Average Volume 15,391
    200-Day Moving Average 6.23
    50-Day Moving Average 4.03
    20-Day Moving Average 3.46
    10-Day Moving Average 2.90
    Average True Range 0.29
    RSI (14) 24.81
    ADX 33.97
    +DI 10.16
    -DI 40.62
    Chandelier Exit (Long, 3 ATRs) 3.64
    Chandelier Exit (Short, 3 ATRs) 3.22
    Upper Bollinger Bands 4.68
    Lower Bollinger Band 2.23
    Percent B (%b) 0.17
    BandWidth 70.75
    MACD Line -0.45
    MACD Signal Line -0.38
    MACD Histogram -0.0711
    Fundamentals Value
    Market Cap 24.35 Million
    Num Shares 9.23 Million
    EPS -5.60
    Price-to-Earnings (P/E) Ratio -0.47
    Price-to-Sales 13.45
    Price-to-Book 3.28
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.89
    Resistance 3 (R3) 2.87 2.75 2.85
    Resistance 2 (R2) 2.75 2.69 2.77 2.84
    Resistance 1 (R1) 2.70 2.65 2.72 2.72 2.82
    Pivot Point 2.58 2.58 2.60 2.60 2.58
    Support 1 (S1) 2.53 2.52 2.56 2.56 2.46
    Support 2 (S2) 2.41 2.48 2.43 2.44
    Support 3 (S3) 2.36 2.41 2.43
    Support 4 (S4) 2.39